
GLSynthesis Inc (AKA: The Fluorosome Company) Profile last edited on: 10/31/23
CAGE: 3R5C7
UEI: UKS9MJNSGBE7
Business Identifier: Custom organic synthesis, drug and chemical product R&D, pharmacology, international chemical production and sales Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 02
County: Worcester
Congr. District: 02
County: Worcester
Public Profile
GLSynthesis performs laboratory scale (custom) organic synthesis for major US and international pharmaceutical companies, startup drug discovery and "virtual" companies, biotechnology companies, and academic and research institutions. The company carries out drug discovery and development research, including synthesis, pharmacokinetic studies and pharmacological testing of drug candidates, through corporate contracts and small business (NIH) grants. The firm is developing the Fluorosome® Technique for passive and active drug absorption studies, and is actively marketing the reagents and equipment. The firm manufactures specialty organic chemicals and pharmaceutical intermediates and supplies these products to customers worldwide. With its expanded operations in China, GLSynthesis provides customers with a full range of chemical manufacturing services, from small scale custom synthesis, to FTE-based contract synthesis, to pilot scale and commercial scale manufacturing. The company's laboratories are in the Massachusetts Biotechnology Research Park, Worcester, MA and its production facilities are in China.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
20-24Revenue Range
2M-2.5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2020 | 2 | NIH | $1,638,274 | |
Project Title: Production and Inhibition Assay for Bile Salt Export Protein | ||||
2017 | 2 | NIH | $1,512,842 | |
Project Title: Development of a Fluorescence Liposomal ABCG2 Multidrug Transporter Assay | ||||
2015 | 2 | NIH | $5,204,906 | |
Project Title: Novel Antithrombotic Diadenosine Tetraphosphate Analogs | ||||
2015 | 1 | NIH | $320,466 | |
Project Title: A Novel Drug Detection Assay Using Fluorescent Biosensor Technology | ||||
2013 | 1 | NIH | $237,357 | |
Project Title: A Soft Topical Antiandrogenic Drug |
Key People / Management
Jan L Chen -- CEO
George E Wright -- President
Praveen Bansal
Vincent B Ciofalo
Sofya Dvoskin
Karsten A Holm
Andrew T Maioli
Donald L Melchior
Paul M Tarantino
George E Wright
Wei-Chu Xu
Ivan B Yanachkov
George E Wright -- President
Praveen Bansal
Vincent B Ciofalo
Sofya Dvoskin
Karsten A Holm
Andrew T Maioli
Donald L Melchior
Paul M Tarantino
George E Wright
Wei-Chu Xu
Ivan B Yanachkov
Company News
There are no news available.